查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485085

前列腺癌診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按測試類型、類型、最終用途、地區和競爭細分，2019-2029F

Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type, By End use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球前列腺癌診斷市場估值為85.2 億美元，預計到2029 年預測期內將穩定成長，複合年成長率為4.25%。癌症之一。早期檢測和準確診斷對於有效治療和改善患者預後至關重要。多年來，全球前列腺癌診斷市場在疾病的早期檢測、診斷和監測技術和方法方面取得了顯著進展。全球前列腺癌診斷市場在過去十年中經歷了大幅成長，這主要是由於癌症盛行率上升、人口老化、早期檢測意識增強以及診斷技術進步等因素。

市場概況
預測期 2025-2029
2023 年市場規模 85.2億美元
2029 年市場規模 106.3億美元
2024-2029 年複合年成長率 4.25%
成長最快的細分市場 驗證性測試
最大的市場 北美洲

該市場涵蓋多種診斷方法，包括生物標記測試、成像和活體組織切片，這些方法在前列腺癌的檢測和管理中發揮關鍵作用。前列腺癌診斷的不斷發展顯著改善了患者護理和治療結果。早期檢測和準確診斷對於制定治療計劃至關重要，治療計劃可能包括手術、放射治療、荷爾蒙治療或主動監測。這些進步可以更精確地對疾病進行分期，減少不必要的干涉並提高患者的整體生活品質。基於遺傳和基因組測試的個人化治療方法正在增強治療的有效性並減少潛在的副作用。患有侵襲性前列腺癌風險較高的患者可以從更早、更積極的干涉措施中受益，而患有惰性疾病的患者可以避免不必要的治療。

主要市場促進因素

攝護腺癌發生率上升

增加研發投資

主要市場挑戰

認知和篩檢有限

侵入性和不舒適的測試

準確性和過度診斷

主要市場趨勢

技術進步

細分市場洞察

測試類型洞察

類型洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球前列腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依測試類型（初步測試、確認測試）
    • 按類型（腺癌、間質細胞癌、其他）
    • 依最終用途（醫院和診所、行動護理中心、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按測試類型
    • 按類型
    • 按最終用途
    • 按地區

第 5 章：亞太地區攝護腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按測試類型
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲前列腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按測試類型
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美前列腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按測試類型
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲攝護腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按測試類型
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲前列腺癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按測試類型
    • 按類型
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球前列腺癌診斷市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • MDx Health, Inc.
  • Myriad Genetics, Inc.
  • Abbott Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Siemens Healthcare AG
  • OPKO Health, Inc.
  • Exact Sciences Corporation

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 22455

Global Prostate Cancer Diagnostics Market was valued at USD 8.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.25% through 2029. Prostate cancer is one of the most prevalent forms of cancer in men, accounting for a significant portion of cancer diagnoses worldwide. Early detection and accurate diagnosis are crucial for effective treatment and improved patient outcomes. Over the years, the global prostate cancer diagnostics market has witnessed remarkable advancements in technology and approaches to early detection, diagnosis, and monitoring of this disease. The global prostate cancer diagnostics market has experienced substantial growth over the last decade, primarily due to factors such as rising cancer prevalence, an aging population, increased awareness about early detection, and advancements in diagnostic technologies.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 8.52 Billion
Market Size 2029USD 10.63 Billion
CAGR 2024-20294.25%
Fastest Growing SegmentConfirmatory tests
Largest MarketNorth America

The market encompasses a wide range of diagnostic methods, including biomarker tests, imaging, and biopsies, which play a critical role in the detection and management of prostate cancer. The evolving landscape of prostate cancer diagnostics has significantly improved patient care and outcomes. Early detection and accurate diagnosis are crucial for tailoring treatment plans, which may include surgery, radiation therapy, hormone therapy, or active surveillance. These advancements enable more precise staging of the disease, reducing unnecessary interventions and improving overall quality of life for patients. Personalized treatment approaches based on genetic and genomic testing are enhancing the effectiveness of therapies and reducing potential side effects. Patients with a higher risk of aggressive prostate cancer can benefit from earlier, more aggressive interventions, while those with indolent forms of the disease may avoid unnecessary treatments.

Key Market Drivers

Rising Incidence of Prostate Cancer

Prostate cancer is one of the most prevalent cancers in men worldwide, and its incidence is on the rise. This alarming trend has prompted significant advancements in the field of prostate cancer diagnostics. As early detection and timely treatment are crucial for improving patient outcomes, the global prostate cancer diagnostics market has witnessed remarkable growth in recent years. Prostate cancer is the second most common cancer in men, after skin cancer. This upward trajectory is not limited to the United States, it is a global concern. Several factors contribute to the increased incidence of prostate cancer, including aging populations, lifestyle choices, and improved screening and diagnostic capabilities.

One of the primary drivers of the rising incidence of prostate cancer is the aging global population. As people live longer, the risk of developing cancer, including prostate cancer, increases. The disease is most commonly diagnosed in men aged 65 and older. Unhealthy lifestyle choices, such as a diet high in saturated fats and low in fruits and vegetables, lack of physical activity, and smoking, have been associated with an increased risk of prostate cancer. The adoption of these habits in many parts of the world has contributed to the disease's prevalence. Advances in medical technology and increased awareness of prostate cancer have led to more men undergoing regular screenings, including the prostate-specific antigen (PSA) test. This has resulted in the detection of prostate cancer at earlier stages, which can lead to a higher incidence rate.

The rising incidence of prostate cancer has driven substantial growth in the global prostate cancer diagnostics market. This market encompasses a wide range of diagnostic tools and techniques, including PSA testing, digital rectal examinations, biopsies, imaging modalities like MRI and ultrasound, and more. The emphasis on early detection has led to the development of more sensitive and accurate diagnostic tools. These advancements enable healthcare professionals to identify prostate cancer at earlier, more treatable stages, resulting in better patient outcomes. Ongoing advancements in diagnostic technologies, such as multiparametric MRI and liquid biopsies, have significantly improved the precision and reliability of prostate cancer diagnosis. These innovations are helping healthcare providers make more informed decisions about treatment strategies. As healthcare spending continues to rise globally, there is increased investment in cancer diagnostics and treatment. This investment has facilitated the development and adoption of advanced diagnostic methods. Awareness campaigns and public health initiatives have encouraged men to seek regular prostate cancer screenings. Greater awareness has been instrumental in early detection, further fueling the demand for diagnostic services. Emerging markets are witnessing a significant expansion in healthcare infrastructure and services, leading to increased access to diagnostic facilities and early detection of prostate cancer.

Increasing Investment in Research and Development

Prostate cancer is one of the most prevalent forms of cancer affecting men worldwide. In recent years, there has been a significant shift in the way we diagnose and treat this disease, driven by a surge in investment in research and development (R&D). This investment has revolutionized the global prostate cancer diagnostics market, leading to more accurate detection, better treatment options, and improved patient outcomes. Research and development are crucial components of advancing healthcare. In the context of prostate cancer diagnostics, R&D plays a pivotal role in developing new and improved diagnostic tools, as well as more effective treatments. The increased investment in this field has accelerated the development of innovative solutions that benefit both patients and healthcare professionals.

The increased investment in R&D has had a profound impact on the global prostate cancer diagnostics market. Several significant developments and trends are shaping the market's growth. Advanced imaging technologies and biomarker discovery have led to more precise and early detection of prostate cancer. This has reduced the need for invasive biopsies and improved patient outcomes. Liquid biopsies, which can detect circulating tumor DNA in blood samples, offer a non-invasive way to diagnose and monitor prostate cancer. These tests provide valuable information about the disease's progression without the need for invasive procedures. R&D efforts have contributed to the development of targeted therapies that are tailored to a patient's specific genetic profile. This precision medicine approach ensures more effective treatment with fewer side effects. Increased R&D investments have led to greater awareness of prostate cancer and its importance for early detection. This, in turn, has encouraged more individuals to undergo screening and diagnostic procedures, leading to earlier interventions. The global prostate cancer diagnostics market is expanding rapidly, with an increasing number of companies and institutions participating in research, development, and commercialization efforts. This has created a competitive market with numerous cutting-edge diagnostic tools and treatments.

Key Market Challenges

Limited Awareness and Screening

One of the primary challenges in prostate cancer diagnostics is the lack of awareness and screening programs, especially in low- and middle-income countries. Early detection significantly increases the chances of successful treatment, but many men remain unaware of the importance of regular screening. This lack of awareness often leads to late-stage diagnoses, which are more difficult to treat and have a higher mortality rate. Limited awareness and screening pose significant challenges in the prostate cancer diagnostics market globally. Despite advancements in screening methods like PSA tests and digital rectal exams, many men remain unaware of the importance of early detection. Cultural stigma, fear, and lack of education contribute to low screening rates, particularly in underserved populations. Varying guidelines and controversies surrounding over diagnosis and overtreatment further complicate screening efforts. Addressing these barriers requires comprehensive awareness campaigns, community outreach programs, and policy initiatives to promote routine screening and educate individuals about the benefits of early detection, ultimately reducing mortality rates associated with prostate cancer.

Invasive and Uncomfortable Tests

The current gold standard for prostate cancer diagnosis is the prostate-specific antigen (PSA) test, which involves drawing a blood sample. However, this test is not without its drawbacks. It can produce false positives, leading to unnecessary biopsies and anxiety for patients. The digital rectal exam (DRE), another common screening method, is invasive and uncomfortable, leading many men to avoid regular check-ups. Invasive and uncomfortable tests are key challenges facing the prostate cancer diagnostics market. Procedures like prostate biopsy, often necessary for definitive diagnosis, can cause discomfort, pain, and anxiety for patients. The potential risks of complications such as infection or bleeding further deter individuals from undergoing testing. Fear and apprehension surrounding these invasive procedures contribute to low screening uptake rates. To address this, the medical community is exploring non-invasive diagnostic methods like MRI and liquid biopsies, which offer promising alternatives for early detection with reduced discomfort and risk. Enhancing patient education and offering supportive care during testing can also mitigate concerns and improve screening rates.

Accuracy and Over diagnosis

False positives and over diagnosis are significant issues in the prostate cancer diagnostics market. PSA tests can indicate elevated levels without cancer being present, leading to unnecessary treatments and potential side effects. This lack of accuracy can create confusion for both healthcare providers and patients, making it difficult to determine the best course of action. Accuracy and over diagnosis are critical considerations in the prostate cancer diagnostics market. While early detection is vital for effective treatment, the inherent challenge lies in distinguishing aggressive cancers requiring intervention from indolent ones that may not progress. Diagnostic tests like PSA screenings often lack specificity, leading to false positives and unnecessary biopsies. Over diagnosis can result in overtreatment, exposing patients to unnecessary risks and healthcare costs. Enhancing the accuracy of diagnostic tools through advancements in imaging and biomarker testing is crucial for minimizing over diagnosis while ensuring timely intervention for clinically significant prostate cancers, thereby improving patient outcomes and healthcare resource utilization.

Key Market Trends

Technological Advancements

Prostate cancer is a major health concern worldwide, affecting millions of men each year. It is one of the most common cancers among men, with early detection and accurate diagnosis being critical for successful treatment. Recent years have witnessed a significant surge in technological advancements in the field of prostate cancer diagnostics, propelling the global market to new heights. These innovations have not only improved the accuracy and reliability of diagnostic tools but have also transformed the overall patient experience.

Technological advancements have revolutionized imaging techniques used in prostate cancer diagnostics. Traditional methods like ultrasound, CT scans, and MRI have been enhanced with newer technologies such as multiparametric MRI (mpMRI) and positron emission tomography (PET) scans. These methods provide more detailed and accurate information about the prostate, allowing for early detection and better treatment planning. Molecular and genetic advancements have paved the way for identifying specific biomarkers associated with prostate cancer. The development of liquid biopsy tests has allowed for the detection of specific genetic mutations and biomarkers in the bloodstream, enabling quicker and less invasive diagnosis and monitoring.

AI and machine learning are being integrated into diagnostic tools to assist healthcare professionals in interpreting complex data. These technologies can analyze imaging and biopsy results, identifying subtle patterns and anomalies that might be overlooked by human observers. This not only improves diagnostic accuracy but also reduces the risk of false positives and unnecessary invasive procedures. The rise of telemedicine and remote monitoring platforms has made it easier for patients to access healthcare services, particularly in the context of prostate cancer diagnostics. Patients can consult with specialists and share their diagnostic data in real-time, ensuring timely and efficient care.

The global prostate cancer diagnostics market is experiencing substantial growth due to these technological advancements. The market is expected to continue expanding at a steady rate, offering lucrative opportunities for healthcare providers, medical device manufacturers, and pharmaceutical companies. The shift towards non-invasive diagnostic methods, such as liquid biopsy tests and advanced imaging, is creating a more patient-friendly and efficient diagnostic process. The global awareness and screening campaigns aimed at early detection are playing a crucial role in market growth. Governments and healthcare organizations are actively promoting routine screening for prostate cancer, which, in combination with advanced diagnostic technologies, enhances the likelihood of early detection and successful treatment.

Segmental Insights

Test Type Insight

Based on Test Type, Confirmatory Tests emerged as the fastest growing segment in the global market for prostate cancer diagnostics in 2023. Confirmatory tests have been introduced to complement screening methods, aiming to provide a more definitive diagnosis. These tests are designed to confirm the presence of prostate cancer and determine its extent and aggressiveness. They are instrumental in avoiding unnecessary procedures, reducing the burden on healthcare systems, and improving the patient experience. Confirmatory tests, such as the multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies, have significantly improved accuracy in diagnosing prostate cancer. mpMRI provides detailed images of the prostate, allowing for better localization of suspicious areas, while targeted biopsies can precisely sample these areas, reducing the chances of missing cancerous lesions. Confirmatory tests help reduce the over diagnosis and overtreatment associated with traditional PSA testing. By confirming the presence and aggressiveness of cancer, they enable more personalized treatment decisions, sparing patients from unnecessary interventions.

Type Insights

Based on type, the Adenocarcinoma segment is projected to experience rapid growth in Global Prostate Cancer Diagnostics Market during the forecast period. Adenocarcinoma's dominance in the global prostate cancer diagnostics market is primarily due to its high prevalence. Most prostate cancers diagnosed are adenocarcinomas, and their incidence rates are significantly higher than other subtypes. Adenocarcinoma has spurred advancements in diagnostic technologies. Early detection and accurate diagnosis are crucial for improving patient outcomes. Techniques like PSA testing, digital rectal examination (DRE), and advanced imaging methods have been optimized to detect and diagnose adenocarcinoma effectively. The prevalence of adenocarcinoma has led to a concentrated focus on treatment strategies. Researchers and clinicians have dedicated considerable resources to developing targeted therapies and personalized treatment plans for adenocarcinoma patients. This focus has led to better management and survival rates. Adenocarcinoma's predominance has fueled extensive clinical research efforts to understand its molecular characteristics and develop new treatment options. This research has given rise to innovative therapies, such as hormone therapy, immunotherapy, and precision medicine approaches, which have improved outcomes for adenocarcinoma patients.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Prostate Cancer Diagnostics Market in 2023, holding the largest market share in terms of value. North America boasts a well-developed healthcare infrastructure with state-of-the-art diagnostic and treatment facilities. Leading medical institutions, research centers, and hospitals in the region have access to cutting-edge diagnostic equipment and expertise. The aging population in North America has led to an increased prevalence of prostate cancer cases. As the risk of prostate cancer rises with age, the demand for advanced diagnostic tools becomes even more critical. This demographic trend has spurred investment in prostate cancer diagnostics. The United States and Canada are home to many innovative biotechnology and pharmaceutical companies that are constantly working on improving prostate cancer diagnostics. These companies invest heavily in research and development to create more accurate and efficient diagnostic tests.

Key Market Players

MDx Health, Inc.

Myriad Genetics, Inc.

Abbott Laboratories, Inc.

F. Hoffman-La Roche Ltd.

Siemens Healthcare AG

OPKO Health, Inc.

Exact Sciences Corporation

Report Scope:

In this report, the Global Prostate Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Diagnostics Market, By Test Type:

    Preliminary Tests Confirmatory Tests

Prostate Cancer Diagnostics Market, By Type:

    Adenocarcinoma Interstitial cell carcinoma Others

Prostate Cancer Diagnostics Market, By End use:

    Hospitals & Clinics Ambulatory Care Centers Others

Prostate Cancer Diagnostics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Diagnostics Market.

Available Customizations:

Global Prostate Cancer Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Prostate Cancer Diagnostics Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Test Type (Preliminary Tests, Confirmatory Tests)
    • 4.2.2. By Type (Adenocarcinoma, Interstitial cell carcinoma, Others)
    • 4.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Test Type
    • 4.3.2. By Type
    • 4.3.3. By End use
    • 4.3.4. By Region

5. Asia Pacific Prostate Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type
    • 5.2.2. By Type
    • 5.2.3. By End use
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Prostate Cancer Diagnostics Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Test Type
        • 5.3.1.2.2. By Type
        • 5.3.1.2.3. By End use
    • 5.3.2. India Prostate Cancer Diagnostics Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Test Type
        • 5.3.2.2.2. By Type
        • 5.3.2.2.3. By End use
    • 5.3.3. Australia Prostate Cancer Diagnostics Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Test Type
        • 5.3.3.2.2. By Type
        • 5.3.3.2.3. By End use
    • 5.3.4. Japan Prostate Cancer Diagnostics Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Test Type
        • 5.3.4.2.2. By Type
        • 5.3.4.2.3. By End use
    • 5.3.5. South Korea Prostate Cancer Diagnostics Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Test Type
        • 5.3.5.2.2. By Type
        • 5.3.5.2.3. By End use

6. Europe Prostate Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Type
    • 6.2.3. By End use
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Prostate Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End use
    • 6.3.2. Germany Prostate Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End use
    • 6.3.3. Spain Prostate Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End use
    • 6.3.4. Italy Prostate Cancer Diagnostics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Test Type
        • 6.3.4.2.2. By Type
        • 6.3.4.2.3. By End use
    • 6.3.5. United Kingdom Prostate Cancer Diagnostics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Test Type
        • 6.3.5.2.2. By Type
        • 6.3.5.2.3. By End use

7. North America Prostate Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Type
    • 7.2.3. By End use
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Prostate Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End use
    • 7.3.2. Mexico Prostate Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End use
    • 7.3.3. Canada Prostate Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End use

8. South America Prostate Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Type
    • 8.2.3. By End use
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Prostate Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End use
    • 8.3.2. Argentina Prostate Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End use
    • 8.3.3. Colombia Prostate Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End use

9. Middle East and Africa Prostate Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Type
    • 9.2.3. By End use
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Prostate Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End use
    • 9.3.2. Saudi Arabia Prostate Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End use
    • 9.3.3. UAE Prostate Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End use

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Prostate Cancer Diagnostics Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. MDx Health, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Myriad Genetics, Inc.
  • 14.3. Abbott Laboratories, Inc.
  • 14.4. F. Hoffman-La Roche Ltd.
  • 14.5. Siemens Healthcare AG
  • 14.6. OPKO Health, Inc.
  • 14.7. Exact Sciences Corporation

15. Strategic Recommendations

16. About Us & Disclaimer